Over 10 years of non-vitamin K antagonist oral anticoagulants: highlights, challenges, and future developments [0.03%]
维生素K拮抗剂以外的口服抗凝药物超过10年的研究：要点、挑战及未来发展
Raffaele De Caterina,Simona Chiusolo
Raffaele De Caterina
Over the past decade, non-vitamin K antagonist oral anticoagulants have revolutionized anticoagulation therapy, offering substantial benefits over traditional vitamin K antagonists. Non-vitamin K antagonist oral anticoagulants offer reduced...
Genetics in arrhythmogenic cardiomyopathies: where are we now and where are we heading to? [0.03%]
心律失常性心肌病中的遗传学：我们现在的研究状况及未来的研究方向？
Andrea Mazzanti,Deni Kukavica,Alessandro Trancuccio et al.
Andrea Mazzanti et al.
Advances in understanding the genetic architecture and novel imaging techniques have profoundly impacted research on arrhythmogenic right ventricular cardiomyopathy (ARVC). As knowledge of ARVC has evolved, so has its classification: origin...
The contemporary role of genetics in cardiovascular medicine: from phenotypes to precision diagnoses [0.03%]
遗传学在心血管医学中的现代作用：从表型到精准诊断
Mario Urtis,Marilena Tagliani,Davide Bondavalli et al.
Mario Urtis et al.
The diagnostic work-up of cardiovascular genetic diseases is emerging as a reference model for precision (cause and phenotype) and personalized medicine (tailored individual management). This approach is expanding across all areas of cardio...
Vincenzo Castiglione,Sabrina Montuoro,Giulia Orlando et al.
Vincenzo Castiglione et al.
Cardiac amyloidosis (CA) is a progressive, underdiagnosed condition caused by the deposition of misfolded proteins in the myocardium, forming amyloid fibrils that impair cardiac structure and function. This review highlights recent advances...
Gennaro Cice,Leonardo Calò
Gennaro Cice
The 'chronic kidney disease' (CKD) definition that best outlines the complex syndrome commonly called 'kidney failure' has become a problem of World Public Health due to its incidence and prevalence and due to exponentially increasing costs...
Cardiovascular risk assessment in daily clinical practice: when and how to use a risk score [0.03%]
日常临床实践中的心血管风险评估：何时以及如何使用风险评分
Germana Panattoni,Pietro Desimone,Federica Toto et al.
Germana Panattoni et al.
Cardiovascular diseases (CVDs) remain a major cause of morbidity and mortality worldwide. The European Society of Cardiology Guidelines encourage the use of risk prediction models to enhance an adequate management of cardiovascular risk fac...
Oral semaglutide: an innovative paradigm in the management of cardiovascular risk in patients with Type 2 diabetes [0.03%]
口服司美格鲁特：二型糖尿病患者心血管风险管理的新范式
Pier Luigi Temporelli
Pier Luigi Temporelli
Cardiovascular (CV) diseases (CVDs) remain a leading global health issue, causing about one-third of all deaths worldwide. Among modifiable CV risk factors (systolic blood pressure, non-HDL cholesterol, diabetes, body mass index, and smokin...
Towards a phenotype profiling of the patients with heart failure and preserved ejection fraction [0.03%]
射血分数保留的心衰患者的表型分析展望
Giovanni Battista Bonfioli,Matteo Pagnesi,Leonardo Calò et al.
Giovanni Battista Bonfioli et al.
The prevalence of heart failure with preserved ejection fraction (HFpEF) is increasing and prognosis remains poor, with a high risk of mortality or hospitalizations for worsening heart failure events. Apart from sodium-glucose cotransporter...
Nicola Pierucci,Domenico Laviola,Marco Valerio Mariani et al.
Nicola Pierucci et al.
Heart failure (HF) represents one of the leading causes of morbidity and mortality worldwide. In recent years, remote monitoring (RM) and telemedicine have emerged as a promising strategy to improve the management of patients with HF, reduc...
Critical analysis of the 2023 ESC guidelines on cardiomyopathy management [0.03%]
2023年ESC心肌病管理指南的批判性分析
Maria Perotto,Carola Pio Loco Detto Gava,Maddalena Rossi et al.
Maria Perotto et al.
The first European Society of Cardiology (ESC) guidelines on the management of cardiomyopathies (CMPs), published 1 year ago, remain highly relevant. These guidelines provide a comprehensive framework to manage the complexity of CMPs, conso...